ClinicalTrials.gg
CompletedNCT05356364INSPIREUpdated Oct 2, 2026

Improving Negative Stressful Perseverations in Insomnia to Revitalize Expecting Moms (INSPIRE)

An interventional study of Cognitive Behavioral Therapy for Insomnia (CBTI) and Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) in Insomnia and Depression, sponsored by Henry Ford Health System. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Henry Ford Health System · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System — 3 open to participants now, 3 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Henry Ford Health System.

Enrollment
6th of 15
100 · median 80
Started
2023
the only one that year
No phase
11 of 17
2 open now
Registered
13th of 17
by date

Among the 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 13th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System, or all of them as a file.
02

Study summary

Nearly half of women develop insomnia during pregnancy, which is associated with increased risk for developing perinatal depression. The purpose of this research is to evaluate the implementability and effectiveness of a mindfulness-based therapy for insomnia relative to cognitive-behavioral therapy for insomnia in pregnant women with insomnia and comorbid depression. The investigators aim to examine whether a mindfulness-based intervention effectiveness reduces symptoms of insomnia and comorbid depression.

Read the detailed description

The investigators will conduct a pilot hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) wherein 100 pregnant women with DSM-5 insomnia disorder and comorbid depression (Edinburgh Postnatal Depression Scale ≥ 10) are randomized to a mindfulness-based intervention--Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)--or Cognitive Behavioral Therapy for Insomnia (CBTI). Patients will be recruited from women's health clinics across Henry Ford Health in Metro Detroit including underserved women, serving as real-world implementation. Per clinic operations since the pandemic, therapies will be via telemedicine to meet patient expectations. Study outcomes will be assessed before and after treatment, then across the first postpartum year.

03

Conditions studied

  • Insomnia
  • Depression

Keywords

  • Pregnancy
  • Postpartum
  • Telemedicine
  • Cognitive arousal
  • Insomnia
  • Depression
  • Mindfulness
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singleton pregnancy, gestational week 14-31.
  2. Insomnia Disorder (acute or chronic).
  3. Insomnia Severity Index (ISI) score ≥ 11.
  4. Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10.
  5. Ensure adequate sleep opportunity.
  6. Age ≥ 18, English-speaking.
  7. Reliable internet access (treatment, assessments)

Exclusion criteria

Exclusion Criteria:

  1. High risk pregnancy (age >40y, pre-eclampsia, any condition deemed serious risk to mother/fetus; hypertension and diabetes allowed).
  2. Active suicidal intent (ideation is allowed).
  3. Night or rotating shift work.
  4. Epworth Sleepiness Scale>15 (Excessive sleepiness)
  5. Health condition unsafe for sleep restriction (bipolar, epilepsy, etc.).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)

    PUMAS combines behavioral sleep strategies with elements from mindfulness-based interventions, and is tailored specifically to meet the unique needs of pregnant women. Behavioral sleep strategies include sleep restriction and stimulus control. Mindfulness elements include guided meditations and engaging in mindful activities. PUMAS consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.

    Behavioral: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)

  • Active comparator
    Cognitive Behavioral Therapy for Insomnia (CBTI)

    CBTI combines behavioral sleep strategies with cognitive therapy. It is the first-line treatment for insomnia as recommended by the American College of Physicians and the American Academy of Sleep Medicine. Behavioral sleep strategies include sleep restriction and stimulus control. Cognitive therapy includes scheduled worry time and challenging dysfunctional beliefs about sleep. CBTI consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.

    Behavioral: Cognitive Behavioral Therapy for Insomnia (CBTI)

Interventions

  • BehavioralCognitive Behavioral Therapy for Insomnia (CBTI)

    cognitive and behavioral treatment for perinatal insomnia.

  • BehavioralPerinatal Understanding of Mindful Awareness for Sleep (PUMAS)

    Mindfulness and behavioral based therapy for perinatal insomnia.

06

What researchers measure

Primary outcomes

  1. Comparative effectiveness between PUMAS and CBTI on acute insomnia effects.

    The Insomnia Severity Index (ISI) is a commonly used self-report measure of insomnia symptoms that has been validated in a perinatal sample. The ISI scores range from 0-28 with higher scores indicating greater insomnia severity.

    Time frame: The investigators will examine change in ISI scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline.

  2. Comparative effectiveness between PUMAS and CBTI on postpartum insomnia effects.

    The Insomnia Severity Index (ISI) is a commonly used self-report measure of insomnia symptoms that has been validated in a perinatal sample. The ISI scores range from 0-28 with higher scores indicating greater insomnia severity.

    Time frame: The investigators will examine changes in ISI scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum..

Secondary outcomes

  1. Comparative effectiveness between PUMAS and CBTI on acute depression effects.

    The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used depression measure in both pregnant and postnatal women. It is validated for use in clinical trials. The EPDS scores range from 0-30 with higher scores indicating greater depression severity.

    Time frame: The investigators will examine change in EPDS scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline.

  2. Comparative effectiveness between PUMAS and CBTI on postpartum depression effects.

    The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used depression measure in both pregnant and postnatal women. It is validated for use in clinical trials. The EPDS scores range from 0-30 with higher scores indicating greater depression severity.

    Time frame: The investigators will examine changes in EPDS scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum.

  3. Comparative effectiveness between PUMAS and CBTI on acute cognitive arousal effects.

    The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in the perinatal population. Scores range form 8-40 with higher scores indicating greater nighttime cognitive arousal.

    Time frame: The investigators will examine change in PSASC scores from Pretreatment Baseline to Posttreatment, the latter will occur 6-9 weeks after Baseline.

  4. Comparative effectiveness between PUMAS and CBTI on postpartum cognitive arousal effects.

    The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in the perinatal population. Scores range form 8-40 with higher scores indicating greater nighttime cognitive arousal.

    Time frame: The investigators will examine changes in PSASC scores across the first postnatal year, which will be assessed at 3, 6, 9, and 12 months postpartum.

07

Study locations

1 site
  • Henry Ford Medical Center
    Novi, Michigan 48377, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Feb 2026, 36 months.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 36 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Apr 2026 → Feb 2026 and completion Apr 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2022
First posted
May 2, 2022
StartActual
Feb 1, 2023
Primary completionActual
Feb 13, 2026was Apr 2026
CompletionActual
Feb 13, 2026was Apr 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Primary completion
Apr 30, 2026→Feb 13, 2026 (actual)
Oct 2, 2026
Study completion
Apr 30, 2026→Feb 13, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Primary completion Apr 30, 2026→Feb 13, 2026 (now actual)
    Study completion Apr 30, 2026→Feb 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05356364
Responsible party
David Kalmbach (Assistant Scientist, Henry Ford Health System) — Principal investigator
First posted
May 2, 2022
Start date
Feb 1, 2023
Primary completion
Feb 13, 2026
Completion
Feb 13, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion